Aryo Shalviri, Caitlin McIntyre and Jake Harris of Blakes explain why the U.S. Supreme Court's decision in Harrington v. Purdue Pharma, which restricts non-consensual third-party releases in Chapter 11 plans, contrasts with Canadian courts' more flexible approach.









